Breast cancer in the personal genomics era

Current Genomics

Volumn 11, Issue 3, 2010, Pages 146-161

  Ellsworth, Rachel E ^a   Decewicz, David J ^b   Shriver, Craig D ^c   Ellsworth, Darrell L ^b,c  

^a Henry M Jackson Foundation for the Advancement of Military Medicine   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c WINDBER RESEARCH INSTITUTE   (United States)

Author keywords

Breast cancer; Gene expression; Genetic tests; Personal genomics; Risk assessment

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; TAMOXIFEN; TRASTUZUMAB;

ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SUSCEPTIBILITY; CLINICAL PRACTICE; EVOLUTIONARY ADAPTATION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOMICS; HUMAN; IMMUNOHISTOCHEMISTRY; PHARMACOGENOMICS; RISK ASSESSMENT; TELANGIECTASIA;

EID: 77952507615     PISSN: 13892029     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920210791110951     Document Type: Article

References (150)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M.J. Cancer statistics, 2009. CA Cancer J. Clin., 2009, 59, 225-249.
2. Breast Cancer Facts and Figures: 2007-2008. American Cancer Society: Atlanta, GA, 2008.
3. Cancer Trends Progress Report - 2007 Update. National Cancer Institute, National Institutes of Health, Department of Health and Human Services: Bethesda, MD, 2007, http://progressreport.cancer.gov.
4. Key, T.; Appleby, P.; Barnes, I.; Reeves, G.; Enogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J. Natl. Cancer Inst., 2002, 94, 606-616.
5. Kaaks, R.; Berrino, F.; Key, T.; Rinaldi, S.; Dossus, L.; Biessy, C.; Secreto, G.; Amiano, P.; Bingham, S.; Boeing, H.; Bueno de Mesquita, H.B.; Chang-Claude, J.; Clavel-Chapelon, F.; Fournier, A.; van Gils, C.H.; Gonzalez, C.A.; Gurrea, A.B.; Critselis, E.; Khaw, K.T.; Krogh, V.; Lahmann, P.H.; Nagel, G.; Olsen, A.; Onland-Moret, N.C.; Overvad, K.; Palli, D.; Panico, S.; Peeters, P.; Quirós, J.R.; Roddam, A.; Thiebaut, A.; Tjønneland, A.; Chirlaque, M.D.; Trichopoulou, A.; Trichopoulos, D.; Tumino, R.; Vineis, P.; Norat, T.; Ferrari, P.; Slimani, N.; Riboli, E. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J. Natl. Cancer Inst., 2005, 97, 755-765.
6. Kaaks, R.; Rinaldi, S.; Key, T.J.; Berrino, F.; Peeters, P.H.M.; Biessy, C.; Dossus, L.; Lukanova, A.; Bingham, S.; Khaw, K.-T.; Allen, N.E.; Bueno-de-Mesquita, H.B.; van Gils, C.H.; Grobbee, D.; Boeing, H.; Lahmann, P.H.; Nagel, G.; Chang-Claude, J.; Clavel-Chapelon, F.; Fournier, A.; Thiébaut, A.; González, C.A.; Quirós, J.R.; Tormo, M.-J.; Ardanaz, E.; Amiano, P.; Krogh, V.; Palli, D.; Panico, S.; Tumino, R.; Vineis, P.; Trichopoulou, A.; Kalapothaki, V.; Trichopoulos, D.; Ferrari, P.; Norat, T.; Saracci, R.; Riboli, E. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr. Relat. Cancer, 2005, 12, 1071-1082.
7. Rim, A.; Chellman-Jeffers, M. Trends in breast cancer screening and diagnosis. Cleve. Clin. J. Med., 2008, 75, S2-S9.
8. Bissonauth, V.; Shatenstein, B.; Ghadirian, P. Nutrition and breast cancer among sporadic cases and gene mutation carriers: An overview. Cancer Detect. Prev., 2008, 32, 52-64.
9. Perou, C.M.; Sørlie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; Rees, C.A.; Pollack, J.R.; Ross, D.T.; Johnsen, H.; Akslen, L.A.; Fluge, Ø.; Pergamenschikov, A.; Williams, C.; Zhu, S.X.; Lønning, P.E.; Børresen-Dale, A.L.; Brown, P.O.; Botstein, D. Molecular portraits of human breast tumours. Nature, 2000, 406, 747-752.
10. Sørlie, T.; Perou, C.M.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; Thorsen, T.; Quist, H.; Matese, J.C.; Brown, P.O.; Botstein, D.; Eystein Lønning, P.; Børresen-Dale, A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA, 2001, 98, 10869-10874.
11. Gort, M.; Broekhuis, M.; Otter, R.; Klazinga, N.S. Improvement of best practice in early breast cancer: actionable surgeon and hospital factors. Breast Cancer Res. Treat., 2007, 102, 219-226.
12. Eisinger, F.; Sobol, H.; Serin, D.; Whorton, J.C. Hereditary breast cancer, circa 1750. Lancet, 1998, 351, 1366.
13. Lynch, H.T. Introduction to Cancer Genetics. In Cancer Genetics, Charles C. Thomas: Springfield, IL, 1976; pp. 3-31.
14. Holm, N.V.; Hauge, M.; Harvald, B. Etiologic factors of breast cancer elucidated by a study of unselected twins. J. Natl. Cancer Inst., 1980, 65, 285-298.
15. Williams, W.R.; Anderson, D.E. Genetic epidemiology of breast cancer: segregation analysis of 200 Danish pedigrees. Genet. Epidemiol., 1984, 1, 7-20.
16. Newman, B.; Austin, M.A.; Lee, M.; King, M.-C. Inheritance of human breast cancer: Evidence for autosomal dominant transmission in high-risk families. Proc. Natl. Acad. Sci. USA, 1988, 85, 3044-3048.
17. Houlston, R.S.; McCarter, E.; Parbhoo, S.; Scurr, J.H.; Slack, J. Family history and risk of breast cancer. J. Med. Genet., 1992, 29, 154-157.
18. Gelehrter, T.D.; Collins, F.S.; Ginsburg, D. Cancer Genetics. In Principles of Medical Genetics, Lippincott, Williams, and Wilkins: Philadelphia, PA, 1998; pp. 245-272.
19. Hall, J.M.; Lee, M.K.; Newman, B.; Morrow, J.E.; Anderson, L.A.; Huey, B.; King, M.C. Linkage of early-onset familial breast cancer to chromosome 17q21. Science, 1990, 250, 1684-1689.
20. Miki, Y.; Swensen, J.; Shattuck-Eidens, D.; Futreal, P.A.; Harshman, K.; Tavtigian, S.; Liu, Q.; Cochran, C.; Bennett, L.M.; Ding, W.; Bell, R.; Rosenthal, J.; Hussey, C.; Tran, T.; McClure, M.; Frye, C.; Hattier, T.; Phelps, R.; Haugen-Strano, A.; Katcher, H.; Yakumo, K.; Gholami, Z.; Shaffer, D.; Stone, S.; Bayer, S.; Wray, C.; Bogden, R.; Dayananth, P.; Ward, J.; Tonin, P.; Narod, S.; Bristow, P.K.; Norris, F.H.; Helvering, L.; Morrison, P.; Rosteck, P.; Lai, M.; Barrett, J.C.; Lewis, C.; Neuhausen, S.; Cannon-Albright, L.; Goldgar, D.; Wiseman, R.; Kamb, A.; Skolnick, M.H. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 1994, 266, 66-71.
21. Wooster, R.; Neuhausen, S.L.; Mangion, J.; Quirk, Y.; Ford, D.; Collins, N.; Nguyen, K.; Seal, S.; Tran, T.; Averill, D.; Fields, P.; Marshall, G.; Narod, S.; Lenoir, G.M.; Lynch, H.; Feunteun, J.; Devilee, P.; Cornelisse, C.J.; Menko, F.H.; Daly, P.A.; Ormiston, W.; McManus, R.; Pye, C.; Lewis, C.M.; Cannon-Albright, L.A.; Peto, J.; Ponder, B.A.J.; Skolnick, M.H.; Easton, D.F.; Goldgar, D.E.; Stratton, M.R. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science, 1994, 265, 2088-2090.
22. Wooster, R.; Bignell, G.; Lancaster, J.; Swift, S.; Seal, S.; Mangion, J.; Collins, N.; Gregory, S.; Gumbs, C.; Micklem, G.; Barfoot, R.; Hamoudi, R.; Patel, S.; Rice, C.; Biggs, P.; Hashim, Y.; Smith, A.; Connor, F.; Arason, A.; Gudmundsson, J.; Ficenec, D.; Kelsell, D.; Ford, D.; Tonin, P.; Bishop, D.T.; Spurr, N.K.; Ponder, B.A.J.; Eeles, R.; Peto, J.; Devilee, P.; Cornelisse, C.; Lynch, H.; Narod, S.; Lenoir, G.; Egilsson, V.; Barkadottir, R.B.; Easton, D.F.; Bentley, D.R.; Futreal, P.A.; Ashworth, A.; Stratton, M.R. Identification of the breast cancer susceptibility gene BRCA2. Nature, 1995, 378, 789-792.
23. Nelson, H.D.; Huffman, L.H.; Fu, R.; Harris, E.L. U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann. Intern. Med., 2005, 143, 362-379.
24. Hartmann, L.C.; Schaid, D.J.; Woods, J.E.; Crotty, T.P.; Myers, J.L.; Arnold, P.G.; Petty, P.M.; Sellers, T.A.; Johnson, J.L.; McDonnell, S.K.; Frost, M.H.; Jenkins, R.B. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N. Engl. J. Med., 1999, 340, 77-84.
25. Domchek, S.M.; Weber, B.L. Clinical management of BRCA1 and BRCA2 mutation carriers. Oncogene, 2006, 25, 5825-5831.
26. Narod, S.A.; Brunet, J.-S.; Ghadirian, P.; Robson, M.; Heimdal, K.; Neuhausen, S.L.; Stoppa-Lyonnet, D.; Lerman, C.; Pasini, B.; de los Rios, P.; Weber, B.; Lynch, H. Hereditary Breast Cancer Clinical Study Group. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet, 2000, 356, 1876-1881.
27. Kriege, M.; Brekelmans, C.T.M.; Boetes, C.; Besnard, P.E.; Zonderland, H.M.; Obdeijn, I.M.; Manoliu, R.A.; Kok, T.; Peterse, H.; Tilanus-Linthorst, M.M.A.; Muller, S.H.; Meijer, S.; Oosterwijk, J.C.; Beex, L.V.A.; Tollenaar, R.A.E.; de Koning, H.J.; Rutgers, E.J.T.; Klijn, J.G.M. Magnetic Resonance Imaging Screening Study Group. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N. Engl. J. Med., 2004, 351, 427-437.
28. Schwartz, G.F.; Hughes, K.S.; Lynch, H.T.; Fabian, C.J.; Fentiman, I.S.; Robson, M.E.; Domchek, S.M.; Hartmann, L.C.; Holland, R.; Winchester, D.J. The Consensus Conference Committee. Proceedings of the International Consensus Conference on Breast Cancer Risk, Genetics, and Risk Management, April, 2007. Cancer, 2008, 113, 2627-2637.
29. Turner, N.C.; Reis-Filho, J.S. Basal-like breast cancer and the BRCA1 phenotype. Oncogene, 2006, 25, 5846-5853.
30. Robson, M.E.; Chappuis, P.O.; Satagopan, J.; Wong, N.; Boyd, J.; Goffin, J.R.; Hudis, C.; Roberge, D.; Norton, L.; Bégin, L.R.; Offit, K.; Foulkes, W.D. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res., 2004, 6, R8-R17.
31. Moller, P.; Evans, D.G.; Reis, M.M.; Gregory, H.; Anderson, E.; Maehle, L.; Lalloo, F.; Howell, A.; Apold, J.; Clark, N.; Lucassen, A.; Steel, C.M. Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. Int. J. Cancer, 2007, 121, 1017-1020.
32. Liebens, F.P.; Carly, B.; Pastijn, A.; Rozenberg, S. Management of BRCA1/2 associated breast cancer: A systematic qualitative review of the state of knowledge in 2006. Eur. J. Cancer, 2007, 43, 238-257.
33. Rennert, G.; Bisland-Naggan, S.; Barnett-Griness, O.; Bar-Joseph, N.; Zhang, S.; Rennert, H.S.; Narod, S.A. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N. Engl. J. Med., 2007, 357, 115-123.
34. Schwartz, M.D.; Lerman, C.; Brogan, B.; Peshkin, B.N.; Halbert, C.H.; DeMarco, T.; Lawrence, W.; Main, D.; Finch, C.; Magnant, C.; Pennanen, M.; Tsangaris, T.; Willey, S.; Isaacs, C. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J. Clin. Oncol., 2004, 22, 1823-1829.
35. Tutt, A.N.; Lord, C.J.; McCabe, N.; Farmer, H.; Turner, N.; Martin, N.M.; Jackson, S.P.; Smith, G.C.; Ashworth, A. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb. Symp. Quant. Biol., 2005, 70, 139-148.
36. Farmer, H.; McCabe, N.; Lord, C.J.; Tutt, A.N.J.; Johnson, D.A.; Richardson, T.B.; Santarosa, M.; Dillon, K.J.; Hickson, I.; Knights, C.; Martin, N.M.B.; Jackson, S.P.; Smith, G.C.M.; Ashworth, A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 2005, 434, 917-921.
37. Tutt, A.; Ashworth, A. Can genetic testing guide treatment in breast cancer? Eur. J. Cancer, 2008, 44, 2774-2780.
38. Thompson, D.; Easton, D. Breast Cancer Linkage Consortium. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am. J. Hum. Genet., 2001, 68, 410-419.
39. Thompson, D.; Easton, D. Breast Cancer Linkage Consortium. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol. Biomarkers Prev., 2002, 11, 329-336.
40. Easton, D.F.; Ford, D.; Biship, D.T. Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am. J. Hum. Genet., 1995, 56, 265-271.
41. Weyandt, J.; Ellsworth, R.E.; Hooke, J.A.; Shriver, C.D.; Ellsworth, D.L. Environmental chemicals and breast cancer risk-a structural chemistry perspective. Curr. Med. Chem., 2008, 15, 2680-2701.
42. King, M.-C.; Marks, J.H.; Mandell, J.B. New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science, 2003, 302, 643-646.
43. Antoniou, A.C.; Sinilnikova, O.M.; Simard, J.; Léoné, M.; Dumont, M.; Neuhausen, S.L.; Struewing, J.P.; Stoppa-Lyonnet, D.; Barjhoux, L.; Hughes, D.J.; Coupier, I.; Belotti, M.; Lasset, C.; Bonadona, V.; Bignon, Y.-J.; Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers Study (GEMO); Rebbeck, T.R.; Wagner, T.; Lynch, H.T.; Domchek, S.M.; Nathanson, K.L.; Garber, J.E.; Weitzel, J.; Narod, S.A.; Tomlinson, G.; Olopade, O.I.; Godwin, A.; Isaacs, C.; Jakubowska, A.; Lubinski, J.; Gronwald, J.; Górski, B.; Byrski, T.; Huzarski, T.; Peock, S.; Cook, M.; Baynes, C.; Murray, A.; Rogers, M.; Daly, P.A.; Dorkins, H.; Epidemiological Study of BRCA1 and BRCA2 Mutation Carriers (EMBRACE); Schmutzler, R.K.; Versmold, B.; Engel, C.; Meindl, A.; Arnold, N.; Neideracher, D.; Deissler, H.; German Consortium for Hereditary Breast and Ovarian Cancer (GCHBOC); Spurdle, A.B.; Chen, X.; Waddell, N.; Cloonan, N.; The Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab); Kirschoff, T.; Offit, K.; Friedman, E.; Kaufmann, B.; Laitman, Y.; Galore, G.; Rennert, G.; Lejbkowicz, F.; Raskin, L.; Andrulis, I.L.; Ilyushik, E.; Ozcelik, H.; Devilee, P.; Vreeswijk, M.P.G.; Greene, M.H.; Prindiville, S.A.; Osorio, A.; Benítez, J.; Zikan, M.; Szabo, C.I.; Kilpivaara, O.; Nevanlinna, H.; Hamann, U.; Durocher, F.; Arason, A.; Couch, F.J.; Easton, D.F.; Chenevix-Trench, G. Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). RAD51 135G-> C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am. J. Hum. Genet., 2007, 81, 1186-1200.
44. Hughes, D.J. Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Fam. Cancer, 2008, 7, 233-244.
45. Chenevix-Trench, G.; Milne, R.L.; Antoniou, A.C.; Couch, F.J.; Easton, D.F.; Goldgar, D.E. CIMBA. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res., 2007, 9, 104.
46. Ford, D.; Easton, D.F.; Stratton, M.; Narod, S.; Goldgar, D.; Devilee, P.; Bishop, D.T.; Weber, B.; Lenoir, G.; Chang-Claude, J.; Sobol, H.; Teare, M.D.; Struewing, J.; Arason, A.; Scherneck, S.; Peto, J.; Rebbeck, T.R.; Tonin, P.; Neuhausen, S.; Barkardottir, R.; Eyfjord, J.; Lynch, H.; Ponder, B.A.J.; Gayther, S.A.; Birch, J.M.; Lindblom, A.; Stoppa-Lyonnet, D.; Bignon, Y.; Borg, A.; Hamann, U.; Haites, N.; Scott, R.J.; Maugard, C.M.; Vasen, H.; Seitz, S.; Cannon-Albright, L.A.; Schofield, A.; Zelada-Hedman, M. Breast Cancer Linkage Consortium. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am. J. Hum. Genet., 1998, 62, 676-689.
47. Nathanson, K.L.; Weber, B.L. Other breast cancer susceptibility genes: searching for more holy grail. Hum. Mol. Genet., 2001, 10, 715-720.
48. Lacroix, M.; Leclercq, G. BreastMed Consortium. The portrait of hereditary breast cancer. Breast Cancer Res. Treat., 2005, 89, 297-304.
49. Gail, M.H.; Brinton, L.A.; Byar, D.P.; Corle, D.K.; Green, S.B.; Schairer, C.; Mulvihill, J.J. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl. Cancer Inst., 1989, 81, 1879-1886.
50. Claus, E.B.; Risch, N.; Thompson, W.D. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer, 1994, 73, 643-651.
51. Berry, D.A.; Parmigiani, G.; Sanchez, J.; Schildkraut, J.; Winer, E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J. Natl. Cancer Inst., 1997, 89, 227-237.
52. Euhus, D.M. Understanding mathematical models for breast cancer risk assessment and counseling. Breast J., 2001, 7, 224-232.
53. Jacobi, C.E.; de Bock, G.H.; Siergerink, B.; van Asperen, C.J. Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? Breast Cancer Res. Treat., 2009, 115, 381-390.
54. Tyrer, J.; Duffy, S.W.; Cuzick, J. A breast cancer prediction model incorporating familial and personal risk factors. Stat. Med., 2004, 23, 1111-1130.
55. Evans, D.G.R.; Howell, A. Breast cancer risk-assessment models. Breast Cancer Res., 2007, 9, 213.
56. MacPherson, G.; Healey, C.S.; Teare, M.D.; Balasubramanian, S.P.; Reed, M.W.R.; Pharoah, P.D.P.; Ponder, B.A.J.; Meuth, M.; Bhattacharyya, N.P.; Cox, A. Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J. Natl. Cancer Inst., 2004, 96, 1866-1869.
57. Dunning, A.M.; Healey, C.S.; Pharoah, P.D.P.; Teare, M.D.; Ponder, B.A.J.; Easton, D.F. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol. Biomarkers Prev., 1999, 8, 843-854.
58. Hirschhorn, J.N.; Daly, M.J. Genome-wide association studies for common diseases and complex traits. Nat. Rev. Genet., 2005, 6, 95-108.
59. Frazer, K.A.; Murray, S.S.; Schork, N.J.; Topol, E.J. Human genetic variation and its contribution to complex traits. Nat. Rev. Genet., 2009, 10, 241-251.
60. Easton, D.F.; Pooley, K.A.; Dunning, A.M.; Pharoah, P.D.P.; Thompson, D.; Ballinger, D.G.; Struewing, J.P.; Morrison, J.; Field, H.; Luben, R.; Wareham, N.; Ahmed, S.; Healey, C.S.; Bowman, R.; the SEARCH collaborators; Meyer, K.B.; Haiman, C.A.; Kolonel, L.K.; Henderson, B.E.; Le Marchand, L.; Brennan, P.; Sangrajrang, S.; Gaborieau, V.; Odefrey, F.; Shen, C.-Y.; Wu, P.-E.; Wang, H.-C.; Eccles, D.; Evans, D.G.; Peto, J.; Fletcher, O.; Johnson, N.; Seal, S.; Stratton, M.R.; Rahman, N.; Chenevix-Trench, G.; Bojesen, S.E.; Nordestgaard, B.G.; Axelsson, C.K.; Garcia-Closas, M.; Brinton, L.; Chanock, S.; Lissowska, J.; Peplonska, B.; Nevanlinna, H.; Fagerholm, R.; Eerola, H.; Kang, D.; Yoo, K.-Y.; Noh, D.-Y.; Ahn, S.-H.; Hunter, D.J.; Hankinson, S.E.; Cox, D.G.; Hall, P.; Wedren, S.; Liu, J.; Low, Y.-L.; Bogdanova, N.; Schürmann, P.; Dörk, T.; Tollenaar, R.A.E.; Jacobi, C.E.; Devilee, P.; Klijn, J.G.M.; Sigurdson, A.J.; Doody, M.M.; Alexander, B.H.; Zhang, J.; Cox, A.; Brock, I.W.; MacPherson, G.; Reed, M.W.R.; Couch, F.J.; Goode, E.L.; Olson, J.E.; Meijers-Heijboer, H.; van den Ouweland, A.; Uitterlinden, A.; Rivadeneira, F.; Milne, R.L.; Ribas, G.; Gonzalez-Neira, A.; Benitez, J.; Hopper, J.L.; McCredie, M.; Southey, M.; Giles, G.G.; Schroen, C.; Justenhoven, C.; Brauch, H.; Hamann, U.; Ko, Y.-D.; Spurdle, A.B.; Beesley, J.; Chen, X.; kConFab; AOCS Management Group; Mannermaa, A.; Kosma, V.-M.; Kataja, V.; Hartikainen, J.; Day, N.E.; Cox, D.R.; Ponder, B.A.J. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 2007, 447, 1087-1093.
61. Hunter, D.J.; Kraft, P.; Jacobs, K.B.; Cox, D.G.; Yeager, M.; Hankinson, S.E.; Wacholder, S.; Wang, Z.; Welch, R.; Hutchinson, A.; Wang, J.; Yu, K.; Chatterjee, N.; Orr, N.; Willett, W.C.; Colditz, G.A.; Ziegler, R.G.; Berg, C.D.; Buys, S.S.; McCarty, C.A.; Spencer Feigelson, H.; Calle, E.E.; Thun, M.J.; Hayes, R.B.; Tucker, M.; Gerhard, D.S.; Fraumeni, J.F., Jr.; Hoover, R.N.; Thomas, G.; Chanock, S.J. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet., 2007, 39, 870-874.
62. Stacey, S.N.; Manolescu, A.; Sulem, P.; Rafnar, T.; Gudmundsson, J.; Gudjonsson, S.A.; Masson, G.; Jakobsdottir, M.; Thorlacius, S.; Helgason, A.; Aben, K.K.; Strobbe, L.J.; Albers-Akkers, M.T.; Swinkels, D.W.; Henderson, B.E.; Kolonel, L.N.; Le Marchand, L.; Millastre, E.; Andres, R.; Godino, J.; Garcia-Prats, M.D.; Polo, E.; Tres, A.; Mouy, M.; Saemundsdottir, J.; Backman, V.M.; Gudmundsson, L.; Kristjansson, K.; Bergthorsson, J.T.; Kostic, J.; Frigge, M.L.; Geller, F.; Gudbjartsson, D.; Sigurdsson, H.; Jonsdottir, T.; Hrafnkelsson, J.; Johannsson, J.; Sveinsson, T.; Myrdal, G.; Grimsson, H.N.; Jonsson, T.; von Holst, S.; Werelius, B.; Margolin, S.; Lindblom, A.; Mayordomo, J.I.; Haiman, C.A.; Kiemeney, L.A.; Johannsson, O.T.; Gulcher, J.R.; Thorsteinsdottir, U.; Kong, A.; Stefansson, K. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet., 2007, 39, 865-869.
63. Gold, B.; Kirchhoff, T.; Stefanov, S.; Lautenberger, J.; Viale, A.; Garber, J.; Friedman, E.; Narod, S.; Olshen, A.B.; Gregersen, P.; Kosarin, K.; Olsh, A.; Bergeron, J.; Ellis, N.A.; Klein, R.J.; Clark, A.G.; Norton, L.; Dean, M.; Boyd, J.; Offit, K. Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc. Natl. Acad. Sci. USA, 2008, 105, 4340-4345.
64. Stacey, S.N.; Manolescu, A.; Sulem, P.; Thorlacius, S.; Gudjonsson, S.A.; Jonsson, G.F.; Jakobsdottir, M.; Bergthorsson, J.T.; Gudmundsson, J.; Aben, K.K.; Strobbe, L.J.; Swinkels, D.W.; van Engelenburg, K.C.A.; Henderson, B.E.; Kolonel, L.N.; Le Marchand, L.; Millastre, E.; Andres, R.; Saez, B.; Lambea, J.; Godino, J.; Polo, E.; Tres, A.; Picelli, S.; Rantala, J.; Margolin, S.; Jonsson, T.; Sigurdsson, H.; Jonsdottir, T.; Hrafnkelsson, J.; Johannsson, J.; Sveinsson, T.; Myrdal, G.; Grimsson, H.N.; Sveinsdottir, S.G.; Alexiusdottir, K.; Saemundsdottir, J.; Sigurdsson, A.; Kostic, J.; Gudmundsson, L.; Kristjansson, K.; Masson, G.; Fackenthal, J.D.; Adebamowo, C.; Ogundiran, T.; Olopade, O.I.; Haiman, C.A.; Lindblom, A.; Mayordomo, J.I.; Kiemeney, L.A.; Gulcher, J.R.; Rafnar, T.; Thorsteinsdottir, U.; Johannsson, O.T.; Kong, A.; Stefansson, K. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet., 2008, 40, 703-706.
65. Garcia-Closas, M.; Hall, P.; Nevanlinna, H.; Pooley, K.; Morrison, J.; Richesson, D.A.; Bojesen, S.E.; Nordestgaard, B.G.; Axelsson, C.K.; Arias, J.I.; Milne, R.L.; Ribas, G.; González-Neira, A.; Benítez, J.; Zamora, P.; Brauch, H.; Justenhoven, C.; Hamann, U.; Ko, Y.-D.; Bruening, T.; Haas, S.; Dörk, T.; Schürmann, P.; Hillemanns, P.; Bogdanova, N.; Bremer, M.; Karstens, J.H.; Fagerholm, R.; Aaltonen, K.; Aittomäki, K.; von Smitten, K.; Blomqvist, C.; Mannermaa, A.; Uusitupa, M.; Eskelinen, M.; Tengström, M.; Kosma, V.-M.; Kataja, V.; Chenevix-Trench, G.; Spurdle, A.B.; Beesley, J.; Chen, X.; Australian Ovarian Cancer Management Group; Kathleen Cuningham Foundation Consortium For Research into Familial Breast Cancer; Devilee, P.; van Asperen, C.J.; Jacobi, C.E.; Tollenaar, R.A.E.; Huijts, P.E.A.; Klijn, J.G.M.; Chang-Claude, J.; Kropp, S.; Slanger, T.; Flesch-Janys, D.; Mutschelknauss, E.; Salazar, R.; Wang-Gohrke, S.; Couch, F.; Goode, E.L.; Olson, J.E.; Vachon, C.; Fredericksen, Z.S.; Giles, G.G.; Baglietto, L.; Severi, G.; Hopper, J.L.; English, D.R.; Southey, M.C.; Haiman, C.A.; Henderson, B.E.; Kolonel, L.N.; Le Marchand, L.; Stram, D.O.; Hunter, D.J.; Hankinson, S.E.; Cox, D.G.; Tamimi, R.; Kraft, P.; Sherman, M.E.; Chanock, S.J.; Lissowska, J.; Brinton, L.A.; Peplonska, B.; Hooning, M.J.; Meijers-Heijboer, H.; Collee, J.M.; van den Ouweland, A.; Uitterlinden, A.G.; Liu, J.; Lin, L.Y.; Yuqing, L.; Humphreys, K.; Czene, K.; Cox, A.; Balasubramanian, S.P.; Cross, S.S.; Reed, M.W.R.; Blows, F.; Driver, K.; Dunning, A.; Tyrer, J.; Ponder, B.A.J.; Sangrajrang, S.; Brennan, P.; McKay, J.; Odefrey, F.; Gabrieau, V.; Sigurdson, A.; Doody, M.; Struewing, J.P.; Alexander, B.; Easton, D.F.; Pharoah, P.D. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet., 2008, 4, e1000054.
66. Antoniou, A.C.; Spurdle, A.B.; Sinilnikova, O.M.; Healey, S.; Pooley, K.A.; Schmutzler, R.K.; Versmold, B.; Engel, C.; Meindl, A.; Arnold, N.; Hofmann, W.; Sutter, C.; Niederacher, D.; Deissler, H.; Caldes, T.; Kämpjärvi, K.; Nevanlinna, H.; Simard, J.; Beesley, J.; Chen, X.; Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab); Neuhausen, S.L.; Rebbeck, T.R.; Wagner, T.; Lynch, H.T.; Issacs, C.; Weitzel, J.; Granz, P.A.; Daly, M.B.; Tomlinson, G.; Olopade, O.I.; Blum, J.L.; Couch, F.J.; Peterlongo, P.; Manoukian, S.; Barile, M.; Radice, P.; Szabo, C.I.; Pereira, L.H.; Greene, M.H.; Rennert, G.; Lejbkowicz, F.; Barnett-Griness, O.; Andrulis, I.L.; Ozcelik, H.; OCGN; Gerdes, A.M.; Caligo, M.A.; Laitman, Y.; Kaufman, B.; Milgrom, R.; Friedman, E.; Swedish BRCA1 and BRCA2 study collaborators; Domcheck, S.M.; Nathanson, K.L.; Osorio, A.; Llort, G.; Milne, R.L.; Benitez, J.; Hamann, U.; Hogervorst, F.B.; Manders, P.; Ligtenberg, M.J.; van den Ooweland, A.M.; DNA-HEBON collaborators; Peock, S.; Cook, M.; Platte, R.; Evans, D.G.; Eeles, R.; Pichert, G.; Chu, C.; Eccles, D.; Davidson, R.; Douglas, F.; EMBRACE; Godwin, A.K.; Barjhoux, L.; Mazoyer, S.; Sobol, H.; Bourdon, V.; Eisinger, F.; Chompret, A.; Capoulade, C.; Bressac-de Paillerets, B.; Lenoir, G.M.; Gauthier-Villars, M.; Houdayer, C.; Stoppa-Lyonnet, D.; GEMO; Chenevix-Trench, G.; Easton, D.F.; CIMBA. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am. J. Hum. Genet., 2008, 82, 937-948.
67. Pharoah, P.D.P.; Antoniou, A.C.; Easton, D.F.; Ponder, B.A.J. Polygenes, risk prediction, and targeted prevention of breast cancer. N. Engl. J. Med., 2008, 358, 2796-2803.
68. Bodmer, W.; Bonilla, C. Common and rare variants in multifactorial susceptibility to common diseases. Nat. Genet., 2008, 40, 695-701.
69. Ambrosone, C.B. The promise and limitations of genome-wide association studies to elucidate the causes of breast cancer. Breast Cancer Res., 2007, 9, 114.
70. Olopade, O.I.; Grushko, T.A.; Nanda, R.; Huo, D. Advances in breast cancer: Pathways to personalized medicine. Clin. Cancer Res., 2008, 14, 7988-7999.
71. Kaye, J. The regulation of direct-to-consumer genetic tests. Hum. Mol. Genet., 2008, 17, R180-R183.
72. Lenzer, J.; Brownlee, S. Knowing me, knowing you. BMJ, 2008, 336, 858-860.
73. Geransar, R.; Einsiedel, E. Evaluating online direct-to-consumer marketing of genetic tests: informed choices or buyers beware? Genet. Test., 2008, 12, 13-23.
74. Hogarth, S.; Javitt, G.; Melzer, D. The current landscape for direct-to-consumer genetic testing: Legal, ethical, and policy issues. Annu. Rev. Genomics Hum. Genet., 2008, 9, 161-182.
75. Sharma, P.; Sahni, N.S.; Tibshirani, R.; Skaane, P.; Urdal, P.; Berghagen, H.; Jensen, M.; Kristiansen, L.; Moen, C.; Sharma, P.; Zaka, A.; Arnes, J.; Sauer, T.; Akslen, L.A.; Schlichting, E.; Børresen-Dale, A.-L.; Lönneborg, A. Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Res., 2005, 7, R634-R644.
76. Sastre-Garau, X.; Jouve, M.; Asselain, B.; Vincent-Salomon, A.; Beuzeboc, P.; Dorval, T.; Durand, J.-C.; Fourquet, A.; Pouillart, P. Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer, 1996, 77, 113-120.
77. Louwman, M.W.J.; Vriezen, M.; van Beek, M.W.P.; Nolthenius-Puylaert, M.C.; van der Sangen, M.J.C.; Roumen, R.M.; Kiemeney, L.A.; Coebergh, J.W.W. Uncommon breast tumors in perspective: Incidence, treatment and survival in the Netherlands. Int. J. Cancer, 2007, 121, 127-135.
78. Kleer, C.G.; van Golen, K.L.; Merajver, S.D. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res., 2000, 2, 423-429.
79. Engel, J.; Eckel, R.; Aydemir, U.; Aydemir, S.; Kerr, J.; Schlesinger-Raab, A.; Dirschedl, P.; Hölzel, D. Determinants and prognoses of locoregional and distant progression in breast cancer. Int. J. Radiat. Oncol. Biol. Phys., 2003, 55, 1186-1195.
80. Ross, J.S.; Harbeck, N. Prognostic and Predictive Factors Overview. In Molecular Oncology of Breast Cancer, Ross, J.S.; Hortobagyi, G.N., Eds.; Jones and Bartlett Publishers: Sudbury, MA, 2005, pp. 128-141.
81. Park, C.C.; Mitsumori, M.; Nixon, A.; Recht, A.; Connolly, J.; Gelman, R.; Silver, B.; Hetelekidis, S.; Abner, A.; Harris, J.R.; Schnitt, S.J. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. J. Clin. Onol., 2000, 18, 1668-1675.
82. Kunos, C.; Latson, L.; Overmoyer, B.; Silverman, P.; Shenk, R.; Kinsella, T.; Lyons, J. Breast conservation surgery achieving >2 mm tumor-free margins results in decreased local-regional recurrence rates. Breast J., 2006, 12, 28-36.
83. Elston, C.W.; Ellis, I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology, 1991, 19, 403-410.
84. Henson, D.E.; Ries, L.; Freedman, L.S.; Carriaga, M. Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer: the basis for a prognostic index. Cancer, 1991, 68, 2142-2149.
85. Robbins, P.; Pinder, S.; de Klerk, N.; Dawkins, H.; Harvey, J.; Sterrett, G.; Ellis, I.; Elston, C. Histological grading of breast carcinomas: a study of interobserver agreement. Hum. Pathol., 1995, 26, 873-879.
86. Ries, L.A.G.; Melbert, D.; Krapcho, M.; Mariotto, A.; Miller, B.A.; Feuer, E.J.; Clegg, L.; Horner, M.J.; Howlader, N.; Eisner, M.P.; Reichman, M.; Edwards, B.K. SEER Cancer Statistics Review, 1975-2004. National Cancer Institute: Bethesda, MD, 2007, http://seer.cancer.gov/csr/1975_2004/.
87. Elledge, R.M.; Fuqua, S.A. Estrogen and Progesterone Receptors. In Diseases of the Breast, Harris, J.R., Ed.; Lippencott, Williams, and Wilkins: Philadelphia, PA, 2000, pp. 471-488.
88. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 2005, 365, 1687-1717.
89. Slamon, D.J.; Godolphin, W.; Jones, L.A.; Holt, J.A.; Wong, S.G.; Keith, D.E.; Levin, W.J.; Stuart, S.G.; Udove, J.; Ullrich, A.; Press, M.F. Studies of the HER-2-neu proto-oncogene in human breast and ovarian cancer. Science, 1989, 244, 707-712.
90. Wolff, A.C.; Hammond, M.E.H.; Schwartz, J.N.; Hagerty, K.L.; Allred, D.C.; Cote, R.J.; Dowsett, M.; Fitzgibbons, P.L.; Hanna, W.M.; Langer, A.; McShane, L.M.; Paik, S.; Pegram, M.D.; Perez, E.A.; Press, M.F.; Rhodes, A.; Sturgeon, C.; Taube, S.E.; Tubbs, R.; Vance, G.H.; van de Vijver, M.; Wheeler, T.M.; Hayes, D.F. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol., 2007, 25, 118-145.
91. Slamon, D.J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med., 2001, 344, 783-792.
92. Irvin, W.J., Jr.; Carey, L.A. What is triple-negative breast cancer? Eur. J. Cancer, 2008, 44, 2799-2805.
93. Urruticoechea, A.; Smith, I.E.; Dowsett, M. Proliferation marker Ki-67 in early breast cancer. J. Clin. Oncol., 2005, 23, 7212-7220.
94. Dowsett, M.; Smith, I.E.; Ebbs, S.R.; Dixon, J.M.; Skene, A.; A'hern, R.; Salter, J.; Detre, S.; Hills, M.; Walsh, G.; IMPACT Trialists Group. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J. Natl. Cancer Inst., 2007, 99, 167-170.
95. Jones, R.L.; Salter, J.; A'hern, R.; Nerurkar, A.; Parton, M.; Reis-Filho, J.S.; Smith, I.E.; Dowsett, M. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res. Treat., 2009, 116, 53-68.
96. Ravdin, P.M.; Siminoff, L.A.; Davis, G.J.; Mercer, M.B.; Hewlett, J.; Gerson, N.; Parker, H.L. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J. Clin. Oncol., 2001, 19, 980-991.
97. Ring, B.Z.; Seitz, R.S.; Beck, R.; Shasteen, W.J.; Tarr, S.M.; Cheang, M.C.; Yoder, B.J.; Budd, G.T.; Nielsen, T.O.; Hicks, D.G.; Estopinal, N.C.; Ross, D.T. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J. Clin. Oncol., 2006, 24, 3039-3047.
98. Hu, Z.; Fan, C.; Oh, D.S.; Marron, J.S.; He, X.; Qaqish, B.F.; Livasy, C.; Carey, L.A.; Reynolds, E.; Dressler, L.; Nobel, A.; Parker, J.; Ewend, M.G.; Sawyer, L.R.; Wu, J.; Liu, Y.; Nanda, R.; Tretiakova, M.; Ruiz Orrico, A.; Dreher, D.; Palazzo, J.P.; Perreard, L.; Nelson, E.; Mone, M.; Hansen, H.; Mullins, M.; Quackenbush, J.F.; Ellis, M.J.; Olopade, O.I.; Bernard, P.S.; Perou, C.M. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics, 2006, 7, 96.
99. Chang, H.Y.; Sneddon, J.B.; Alizadeh, A.A.; Sood, R.; West, R.B.; Montgomery, K.; Chi, J.-T.; van de Rijn, M.; Botstein, D.; Brown, P.O. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biology, 2004, 2, 206-214.
100. Chang, H.Y.; Nuyten, D.S.A.; Sneddon, J.B.; Hastie, T.; Tibshirani, R.; Sørlie, T.; Dai, H.; He, Y.D.; van't Veer, L.J.; Bartelink, H.; van de Rijn, M.; Brown, P.O.; van de Vijver, M.J. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl. Acad. Sci. USA, 2005, 102, 3738-3743.
101. Nuyten, D.S.A.; Kreike, B.; Hart, A.A.M.; Chi, J.-T.A.; Sneddon, J.B.; Wessels, L.F.A.; Peterse, H.J.; Bartelink, H.; Brown, P.O.; Chang, H.Y.; van de Vijver, M.J. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res., 2006, 8, R62.
102. Chi, J.-T.; Wang, Z.; Nuyten, D.S.A.; Rodriguez, E.H.; Schaner, M.E.; Salim, A.; Wang, Y.; Kristensen, G.B.; Helland, A.; Børresen-Dale, A.-L.; Giaccia, A.; Longaker, M.T.; Hastie, T.; Yang, G.P.; van de Vijver, M.J.; Brown, P.O. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med., 2006, 3, e47.
103. Sotiriou, C.; Wirapati, P.; Loi, S.; Harris, A.; Fox, S.; Smeds, J.; Nordgren, H.; Farmer, P.; Praz, V.; Haibe-Kains, B.; Desmedt, C.; Larsimont, D.; Cardoso, F.; Peterse, H.; Nuyten, D.; Buyse, M.; van de Vijver, M.J.; Bergh, J.; Piccart, M.; Delorenzi, M. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst., 2006, 98, 262-272.
104. Loi, S.; Haibe-Kains, B.; Desmedt, C.; Lallemand, F.; Tutt, A.M.; Gillet, C.; Ellis, P.; Harris, A.; Bergh, J.; Foekens, J.A.; Klijn, J.G.M.; Larsimont, D.; Buyse, M.; Bontempi, G.; Delorenzi, M.; Piccart, M.J.; Sotiriou, C. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J. Clin. Oncol., 2007, 25, 1239-1246.
105. van't Veer, L.J.; Dai, H.; van de Vijver, M.J.; He, Y.D.; Hart, A.A.M.; Mao, M.; Peterse, H.L.; van der Kooy, K.; Marton, M.J.; Witteveen, A.T.; Schreiber, G.J.; Kerkhoven, R.M.; Roberts, C.; Linsley, P.S.; Bernards, R.; Friend, S.H. Gene expression profiling predicts clinical outcome of breast cancer. Nature, 2002, 415, 530-536.
106. van de Vijver, M.J.; He, Y.D.; van't Veer, L.J.; Dai, H.; Hart, A.A.M.; Voskuil, D.W.; Schreiber, G.J.; Peterse, J.L.; Roberts, C.; Marton, M.J.; Parrish, M.; Atsma, D.; Witteveen, A.; Glas, A.; Delahaye, L.; van der Velde, T.; Bartelink, H.; Rodenhuis, S.; Rutgers, E.T.; Friend, S.H.; Bernards, R. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med., 2002, 347, 1999-2009.
107. Wang, Y.; Klijn, J.G.M.; Zhang, Y.; Sieuwerts, A.M.; Look, M.P.; Yang, F.; Talantov, D.; Timmermans, M.; Meijer-van Gelder, M.E.; Yu, J.; Jatkoe, T.; Berns, E.M.J.; Atkins, D.; Foekens, J.A. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet, 2005, 365, 671-679.
108. Paik, S.; Shak, S.; Tang, G.; Kim, C.; Baker, J.; Cronin, M.; Baehner, F.L.; Walker, M.G.; Watson, D.; Park, T.; Hiller, W.; Fisher, E.R.; Wickerham, D.L.; Bryant, J.; Wolmark, N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med., 2004, 351, 2817-2826.
109. Paik, S.; Tang, G.; Shak, S.; Kim, C.; Baker, J.; Kim, W.; Cronin, M.; Baehner, F.L.; Watson, D.; Bryant, J.; Costantino, J.P.; Geyer, C.E., Jr.; Wickerham, D.L.; Wolmark, N. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol., 2006, 24, 3726-3734.
110. Cardoso, F.; Piccart-Gebhart, M.; van't Veer, L.; Rutgers, E.; TRANSBIG Consortium. The MINDACT trial: the first prospective clinical validation of a genomic tool. Mol. Oncol., 2007, 1, 246-251.
111. Sparano, J.A.; Paik, S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J. Clin. Oncol., 2008, 26, 721-728.
112. Desmedt, C.; Ruíz-García, E.; André, F. Gene expression predictors in breast cancer: current status, limitations and perspectives. Eur. J. Cancer, 2008, 44, 2714-2720.
113. Fan, C.; Oh, D.S.; Wessels, L.; Weigelt, B.; Nuyten, D.S.A.; Nobel, A.B.; van't Veer, L.J.; Perou, C.M. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med., 2006, 355, 560-569.
114. Ross, J.S.; Hatzis, C.; Fraser Symmans, W.; Pusztai, L.; Hortobágyi, G.N. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist, 2008, 13, 477-493.
115. Ross, J.S. Multigene predictors in early-stage breast cancer: moving in or moving out? Expert Rev. Mol. Diagn., 2008, 8, 129-135.
116. Pusztai, L.; Stec, J.; Ayers, M.; Ross, J.S.; Wagner, P.; Rouzier, R.; Symmans, F.; Hortobagyi, G.N. Pharmacogenetics, Pharmaco-genomics, and Predicting Response to Therapy. In Molecular Oncology of Breast Cancer, Ross, J.S.; Hortobagyi, G.N., Eds.; Jones and Bartlett Publishers: Sudbury, MA, 2005, pp. 439-456.
117. Jordan, V.C. Tamoxifen: a most unlikely pioneering medicine. Nat. Rev. Drug Discov., 2003, 2, 205-213.
118. Fisher, B.; Costantino, J.P.; Wickerham, D.L.; Redmond, C.K.; Kavanah, M.; Cronin, W.M.; Vogel, V.; Robidoux, A.; Dimitrov, N.; Atkins, J.; Daly, M.; Wieand, S.; Tan-Chiu, E.; Ford, L.; Wolmark, N.; National Surgical Adjuvant Breast and Bowel Project Investigators. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst., 1998, 90, 1371-1388.
119. Bradford, L.D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics, 2002, 3, 229-243.
120. Schroth, W.; Goetz, M.P.; Hamann, U.; Fasching, P.A.; Schmidt, M.; Winter, S.; Fritz, P.; Simon, W.; Suman, V.J.; Ames, M.M.; Safgren, S.L.; Kuffel, M.J.; Ulrich Ulmer, H.; Boländer, J.; Strick, R.; Beckmann, M.W.; Koelbl, H.; Weinshilboum, R.M.; Ingle, J.N.; Eichelbaum, M.; Schwab, M.; Brauch, H. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA, 2009, 302, 1429-1436.
121. Goetz, M.P.; Rae, J.M.; Suman, V.J.; Safgren, S.L.; Ames, M.M.; Visscher, D.W.; Reynolds, C.; Couch, F.J.; Lingle, W.L.; Flockhart, D.A.; Desta, Z.; Perez, E.A.; Ingle, J.N. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol., 2005, 23, 9312-9318.
122. Tan, S.-H.; Lee, S.-C.; Goh, B.-C.; Wong, J. Pharmacogenetics in breast cancer therapy. Clin. Cancer Res., 2008, 14, 8027-8041.
123. Higgins, M.J.; Rae, J.M.; Flockhart, D.A.; Hayes, D.F.; Stearns, V. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing? J. Natl. Compr. Canc. Netw., 2009, 7, 203-213.
124. Dowsett, M.; Haynes, B.P. Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen. J. Steroid Biochem. Mol. Biol., 2003, 86, 255-263.
125. Breast International Group (BIG) 1-98 Collaborative Group; Thürlimann, B.; Keshaviah, A.; Coates, A.S.; Mouridsen, H.; Mauriac, L.; Forbes, J.F.; Paridaens, R.; Castiglione-Gertsch, M.; Gelber, R.D.; Rabaglio, M.; Smith, I.; Wardley, A.; Price, K.N.; Goldhirsch, A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med., 2005, 353, 2747-2757.
126. Boccardo, F.; Rubagotti, A.; Puntoni, M.; Guglielmini, P.; Amoroso, D.; Fini, A.; Paladini, G.; Mesiti, M.; Romeo, D.; Rinaldini, M.; Scali, S.; Porpiglia, M.; Benedetto, C.; Restuccia, N.; Buzzi, F.; Franchi, R.; Massidda, B.; Distante, V.; Amadori, D.; Sismondi, P. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J. Clin. Oncol., 2005, 23, 5138-5147.
127. Goss, P.E.; Ingle, J.N.; Martino, S.; Robert, N.J.; Muss, H.B.; Piccart, M.J.; Castiglione, M.; Tu, D.; Shepherd, L.E.; Pritchard, K.I.; Livingston, R.B.; Davidson, N.E.; Norton, L.; Perez, E.A.; Abrams, J.S.; Cameron, D.A.; Palmer, M.J.; Pater, J.L. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl. Cancer Inst., 2005, 97, 1262-1271.
128. Ma, C.X.; Adjei, A.A.; Salavaggione, O.E.; Coronel, J.; Pelleymounter, L.; Wang, L.; Eckloff, B.W.; Schaid, D.; Wieben, E.D.; Adjei, A.A.; Weinshilboum, R.M. Human aromatase: gene resequencing and functional genomics. Cancer Res., 2005, 65, 11071-11082.
129. Nahta, R.; Esteva, F.J. Herceptin: mechanisms of action and resistance. Cancer Lett., 2006, 232, 123-138.
130. Harris, M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol., 2004, 5, 292-302.
131. Holbro, T.; Beerli, R.R.; Maurer, F.; Koziczak, M.; Barbas, C.F., III, Hynes, N.E. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA, 2003, 100, 8933-8938.
132. Lee-Hoeflich, S.T.; Crocker, L.; Yao, E.; Pham, T.; Munroe, X.; Hoeflich, K.P.; Sliwkowski, M.X.; Stern, H.M. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res., 2008, 68, 5878-5887.
133. Agus, D.B.; Akita, R.W.; Fox, W.D.; Lewis, G.D.; Higgins, B.; Pisacane, P.I.; Lofgren, J.A.; Tindell, C.; Evans, D.P.; Maiese, K.; Scher, H.I.; Sliwkowski, M.X. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell, 2002, 2, 127-137.
134. Moulder, S.; Hortobagyi, G.N. Advances in the treatment of breast cancer. Clin. Pharmacol. Ther., 2008, 83, 26-36.
135. Troester, M.A.; Hoadley, K.A.; Sørlie, T.; Herbert, B.-S.; Børresen-Dale, A.-L.; Lønning, P.E.; Shay, J.W.; Kaufmann, W.K.; Perou, C.M. Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res., 2004, 64, 4218-4226.
136. Rouzier, R.; Perou, C.M.; Symmans, W.F.; Ibrahim, N.; Cristofanilli, M.; Anderson, K.; Hess, K.R.; Stec, J.; Ayers, M.; Wagner, P.; Morandi, P.; Fan, C.; Rabiul, I.; Ross, J.S.; Hortobagyi, G.N.; Pusztai, L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res., 2005, 11, 5678-5685.
137. Li, L.-F.; Xu, X.-J.; Zhao, Y.; Liu, Z.-B.; Shen, Z.-Z.; Jin, W.-R.; Shao, Z.-M. Integrated gene expression profile predicts prognosis of breast cancer patients. Breast Cancer Res. Treat., 2009, 113, 231-237.
138. Chang, J.C.; Wooten, E.C.; Tsimelzon, A.; Hilsenbeck, S.G.; Gutierrez, M.C.; Elledge, R.; Mohsin, S.; Osborne, C.K.; Chamness, G.C.; Allred, D.C.; O'Connell, P. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet, 2003, 362, 362-369.
139. Bosch, T.M.; Meijerman, I.; Beijnen, J.H.; Schellens, J.H.M. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin. Pharmacokinet., 2006, 45, 253-285.
140. Marsh, S.; Liu, G. Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy. Adv. Drug Deliv. Rev., 2009, 61, 381-387.
141. Hoskins, J.M.; Carey, L.A.; McLeod, H.L. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer, 2009, 9, 576-586.
142. Fan, L.; Goh, B.-C.; Wong, C.-I.; Sukri, N.; Lim, S.-E.; Tan, S.-H.; Guo, J.-Y.; Lim, R.; Yap, H.-L.; Khoo, Y.-M.; Iau, P.; Lee, H.-S.; Lee, S.-C. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity. Pharmacogenet. Genomics, 2008, 18, 621-629.
143. Ambrosone, C.B.; Ahn, J.; Singh, K.K.; Rezaishiraz, H.; Furberg, H.; Sweeney, C.; Coles, B.; Trovato, A. Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer. Cancer Res., 2005, 65, 1105-1111.
144. Harris, L.; Fritsche, H.; Mennel, R.; Norton, L.; Ravdin, P.; Taube, S.; Somerfield, M.R.; Hayes, D.F.; Bast, R.C., Jr. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol., 2007, 25, 5287-5312.
145. Check Hayden, E. Personalized cancer therapy gets closer. Nature, 2009, 458, 131-132.
146. Manolio, T.A.; Brooks, L.D.; Collins, F.S. A HapMap harvest of insights into the genetics of common disease. J. Clin. Invest., 2008, 118, 1590-1605.
147. Phillips, K.A.; Veenstra, D.L.; Ramsey, S.D.; Van Bebber, S.L.; Sakowski, J. Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. Am. J. Manag. Care, 2004, 10, 425-432.
148. Salari, K. The dawning era of personalized medicine exposes a gap in medical education. PLoS Med., 2009, 6, e1000138.
149. Chang-Claude, J.; Ambrosone, C.B.; Lilla, C.; Kropp, S.; Helmbold, I.; von Fournier, D.; Haase, W.; Sautter-Bihl, M.-L.; Wenz, F.; Schmezer, P.; Popanda, O. Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer. Br. J. Cancer, 2009, 100, 1680-1686.
150. Zárate, R.; González-Santigo, S.; de la Haba, J.; Bandres, E.; Morales, R.; Salgado, J.; Gómez, A.; Aranda, E.; García-Foncillas, J. GSTP1 and MTHFR polymorphisms are related with toxicity in breast cancer adjuvant anthracycline-based treatment. Curr. Drug Metab., 2007, 8, 481-486.